生物活性检测方法在生物制品研发和质量控制中发挥着关键作用,近年来对该类方法的方法学研究也取得了长足进展。本文首先回顾生物活性检测方法研究的历史进程;其次,对国内外的药典、法规及技术指南中的生物活性检测方法内容进行梳理;最后,对生物活性检测方法学相关的最新进展进行概述和分析,包括分析方法生命周期、分析目标概要等新概念的介绍。希望本文能为药品行业相关人员全面了解国内外药品生物活性检测方法及其相关指导原则提供参考。同时,也希望为药品研发人员建立科学、可靠的生物活性检测方法提供理论支持。
Bioassays play a key role in the development and quality control of biological products, and the research on them has also made great progress in recent years. Here, the historical process of bioassays was reviewed. Then- the current contents about bioassays in pharmacopoeia and technical guidelines weresorted out. At last, the latest progress related to bioassays was summarized and analyzed including the introduction of new concepts such as analytical procedure, method life cycle and analytical target profile.This paper might provide a systematical reference for the people work in the biopharmaceutical field to fully understand the bioassays and related guidelines. Meanwhile, it can also provide a theoretical support for drug researchers to establish scientific and reliable bioassays.
[1] 中华人民共和国药典2020年版.四部[S].2020: 658,530
ChP 2020.Vol Ⅳ [S].2020:658,530
[2] HOSKINS WM, CRAIG R. Uses of bioassay in entomology [J].Annu Rev Entomol, 1962,7(1):437
[3] U.S Food & Drug Administration. Potency Tests for Cellular and Gene Therapy Products-Final Guidance for Industry[EB/OL].(2011-01-01) [2022-02-06].
https://www.fda.gov/regulatory-information/search-fda-guidance-documents/potency-tests-cellular-and-gene-therapy-products
[4] BARNETT KL, MCGREGOR PL, MARTIN GP, et al. Analytical target profile: stucture and application throughout the analytical lifecycle [J].Pharmacopeial Forum, 2016, 42(5): 274
[5] ICH Q2(R1)Harmonised Tripartite Guideline. Validation of Analytical Procedure: Test and Methodology[S].2005
[6] 谭德讲,朱容蝶,耿颖,等.判断定量类理化分析方法满足预期用途的标准探讨[J].药物分析杂志,2019,39(2):196
TAN DJ, ZHU RD, GENG Y, et al. Discussion about the criteria of quantitative physicochemical analytical methods for satisfying their intended use[J].Chin J Pharm Anal, 2019, 39(2): 196
[7] 朱容蝶,耿颖,谭德讲,等.方法验证性能参数的获取和评价方式再探讨[J].药物分析杂志,2019,39(2):202
ZHU RD, GENG Y, TAN DJ, et al. Further discussion about the acquisition and evaluation of performance parameters in procedure validation[J].Chin J Pharm Anal, 2019, 39(2): 202
[8] FINNEY DJ. Statistical Method in Biological Assay [M].3rd Ed. London: Alden Press,1978:1
[9] NOORDWIJK JV. Bioassays in who leanimals[J].J Pharm Biomed Anal, 1989, 7(2):139
[10] GADDUM JH. Bioassays and mathematics[J].Pharmacol Rev,1953, 5:87
[11] BLISS CI, CATTELL M. Biological assay[J].Annu Rev Physiol,1943, 5: 479
[12] CHARALAMBOUS G. Analysis of Foods and Beverages: Modern Techniques [M].Orlando:Academic Press, 1984:1
[13] BOSCH F, ROSICH L. The contributions of paul ehrlich to pharmacology: a tribute on the occasion of the centenary of his Nobel Prize[J].Pharmacology,2008, 82(3):171
[14] BEYER LA, BECK BD, LEWANDOWSKI TA. Historical perspective on the use of animal bioassays to predict carcinogenicity: Evolution in design and recognition of utility[J].Crit Rev Toxicol, 2011, 41(4):321
[15] 周海钧,申蕴如. 生物检定统计方法[M]. 第二版.北京:人民卫生出版社,1988:1
ZHOU HJ, SHEN YR. Statistical Methods for Biological Assays [M].2nd Edit. Beijing: People’s Medical Press, 1988:1
[16] 周海钧. 药品生物检定[M].北京:人民卫生出版社,2005:1
ZHOU HJ. Biological Assay of Drugs [M].Beijing: People’s Medical Publishing House, 2005:1
[17] 孙瑞元. 定量药理学[M].北京:人民卫生出版社,1987:1
SUN RY.Quantitative Pharmacology [M].Beijing: People’s Medical Publishing House, 1987:1
[18] 冷炜. 药品的生物检定[M].北京:气象出版社,1995:6
LENG W.Biological Assay of Drugs [M].Beijing: China Meteorological Press,1995:6
[19] USP 36-NF 31.Vol 1[S].2013: 496, 510, 521
[20] U.S Food & Drug Administration:Analytical Procedures and Methods Validation for Drugs and Biologics [EB/OL].(2015-07-27) [2022-02-06].https://www.fda.gov/regulatory-information/search-fda-guidance-documents/analytical-procedures-and-methods-validation-drugs-and-biologics
[21] USP XV[S].1955: 865
[22] EP. Vol Ⅱ[S].1971: 441
[23] BP. Vol Ⅱ[S].1980: A156
[24] 中华人民共和国药典1985年版.二部[S].1985:附录62
ChP 1985.Vol Ⅱ[S].1985:Appendix 62
[25] USP 39-NF 34. Vol 1[S].2016: 187, 877
[26] EP 4.0[S].2002:427
[27] EP 4.7[S].2004:4375
[28] USP 37-NF 32. Vol Ⅰ[S].2014:555, 869, 876, 885, 894, 909
[29] USP Validation and Verification Expert Panel. Proposed new USP general chapter: the analytical procedure lifecycle <1220> [J].Pharmacop Forum, 2017, 43(1):317
[30] 袁和军.新通则/分析方法生命周期[EB/OL].(2021-11-03) [2022-02-06].https://mp.weixin.qq.com/s/yaKUXVSRAoNBrzANR4UbTQ
YUAN HJ.New General Chapters/ Analytical Procedure Life Cycle [EB/OL].(2021-11-03) [2022-0206].https://mp.weixin.qq.com/s/yaKUXVSRAoNBrzANR4UbTQ
[31] ICH Prepares for Future New Topics [EB/OL].(2018-06-22) [2022-02-06].https://www.ich.org/pressrelease/ich-assembly-kobe-japan-june-2018
[32] 沈连忠,李波.中国药典生物检定统计软件BS2000 For Windows 9X[J].中国卫生统计,2000,17(6):330
SHEN LZ,LI B.Chinese pharmacopoeia bioassay statistical software BS2000 for Windows 9X[J].Chin J Health Stat, 2000, 17(6):330
[33] 项荣武,梁露花,党丹,等.中、美、欧药典关于生物检定统计法的比较[J].沈阳药科大学学报,2014,31(10):819
XIANG RW, LIANG LH, DANG D, et al. A comparison of the bioassay statistical method in ChP with those in USP and EP[J].J Shenyang Pharm Univ, 2014, 31(10): 819
[34] 谭德讲,朱容蝶,耿颖,等. 分析方法验证国内外技术指南现状分析[J].药物分析杂志,2019,39(2):191
TAN DJ, ZHU RD, GENG Y, et al. Analysis of the current status of domestic and foreign guidelines for method validation[J].Chin J Pharm Anal, 2019, 39(2): 191
[35] 韩璐,隋思涟,谭德讲,等.生物活性检测方法验证统计分析软件的设计和功能[J].药物分析杂志,2022,42(6):979
HAN L, SUI SL, TAN DJ, et al. Design and function of statistical software for validation of biological method[J].Chin J Pharm Anal, 2022, 42(6):979
